Research progress in reactivation factors and prevention of retinopathy of prematurity after anti-VEGF therapy
10.3760/cma.j.cn115989-20211116-00633
- VernacularTitle:抗VEGF疗法治疗早产儿视网膜病变后复活因素及防治研究进展
- Author:
Yusheng ZHONG
1
;
Jianhong LIANG
1
;
Xiaoxin LI
1
;
Yong CHENG
1
Author Information
1. 北京大学人民医院眼科 眼病与视光医学北京市重点实验室，北京 100044
- Publication Type:Journal Article
- Keywords:
Retinopathy of prematurity;
Vascular endothelial growth factor;
Reactivation;
Prevention;
Treatment;
Review
- From:
Chinese Journal of Experimental Ophthalmology
2025;43(8):761-765
- CountryChina
- Language:Chinese
-
Abstract:
The intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is currently the first-line therapy for retinopathy of prematurity (ROP) in clinical practice.This therapy has several advantages, including ease of operation, rapid onset of action, and minimal adverse reactions.However, the high reactivation rate observed in clinical applications limits its utility.Understanding reactivation characteristics is crucial for patient management and clinical trial design.The International Classification of Retinopathy of Prematurity (Third edition) updated the definition of reactivation and related concepts.This article summarizes the clinical manifestations and mechanisms of ROP reactivation after anti-VEGF therapy in recent studies and analyzes high-risk factors associated with reactivation, including those related to the infant, the disease, and the medication.The goal is to provide guidance for the early identification, prevention, and intervention in clinical practice.Nevertheless, significant clinical controversies remain regarding the prevention and retreatment of ROP reactivation.Future research should accumulate more evidence-based medical data and conduct large-scale prospective studies to further standardize diagnostic and treatment processes.
